Malignant Tumor
51
11
13
17
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.9%
2 terminated out of 51 trials
89.5%
+3.0% vs benchmark
4%
2 trials in Phase 3/4
0%
0 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (51)
Clinical Study of Novel Therapeutic Vaccine for Advanced Solid Tumors
First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2
Stimulation of Acupuncture Points by Athermic Laser Therapy for the Prevention of Chemotherapy Induced Nausea and Vomiting in Children
Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors
Rehabilitation Outcomes Study
Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease
Effectiveness of Central Oncology Navigation and the Use of an ORN
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
A Study of Diffusing Alpha Radiation Therapy for Target Treatments of Malignant Tumors
Psychological Distress in Malignant Tumor Patients: Effects on Treatment Adherence, Outcomes, and Quality of Life
A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors
First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
Impact of Family-Centered Empowerment on Caregivers of Children with Cancer: a Quasi-Experimental Study Protocol
Establishment of Tongue Image Database and Machine Learning Model for Malignant Tumors Diagnosis
XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study)
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Application of Douyin in Patients With Bone and Soft Tissue Malignant Tumors During Perichemotherapy